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Mouse modelSelenium (Se) is an essential micronutrient. Its biological functions are associated with selenoproteins, which con-
tain this trace element in the formof the 21st amino acid, selenocysteine. Genetic defects in selenocysteine insertion
into proteins are associated with severe health issues. The consequences of selenoprotein deﬁciency are more var-
iable,with several selenoproteins being essential, and several showing no clear phenotypes.Much of these function-
al studies beneﬁted from theuse of rodentmodels anddiets employing variable levels of Se. This review summarizes
the data obtained with these models, focusing on mouse models with targeted expression of individual selenopro-
teins and removal of individual, subsets or all selenoproteins in a systemic or organ-speciﬁc manner. This article is
part of a Special Issue entitled: Cell Biology of Metals.
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Glutathione peroxidase 1 (GPx1) [1] was the ﬁrst identiﬁed sele-
noprotein. Initially isolated from human erythrocytes, it was shown
to protect hemoglobin from oxidative damage. Later, it was found to
be dependent on selenium (Se), [2–5]. Se is incorporated into GPx1
in the form of the 21st amino acid, selenocysteine (Sec). In comparison
to cysteine (Cys), Sec has a lower pKa and is a stronger nucleophile [6].
Almost all known selenoproteins are oxidoreductases with Sec in the
active center. Sec insertion requires the presence of an in-frame UGA
codon and the Sec insertion sequence (SECIS) element, a kink-turn
RNA structure. In eukaryotes, the SECIS element is located in the 3′
UTRs of selenoprotein mRNAs. Biosynthesis of Sec occurs on its owneiodinase type 1; DI2, thyroid
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rights reserved.tRNA, tRNA[Ser]Sec, which is initially charged with Ser. SECIS-binding
protein 2 (SBP2 or Secisbp2) binds the SECIS element and recruits
Sec-tRNA[Ser]Sec along with other factors involved in Sec insertion
[7,8]. Characterization of the structure and conserved sequences of
the SECIS element allowed development of computational programs
for identiﬁcation of selenoprotein genes in sequence databases
[9–11]. The SECISearch program was designed to recognize
sequence, structural and thermodynamic parameters of SECIS ele-
ments [12]. By searching for SECIS elements, in-frame UGA codons in
the ORFs and the presence of Cys-containing orthologs of selenopro-
teins, selenoprotein genes could be identiﬁed in genomic sequences.
Accordingly, the human genome was found to contain 25 selenopro-
tein genes (Table 1). Most of these proteins participate in maintaining
cellular redox homeostasis, including three thioredoxin reductases
(TRs), ﬁve glutathione peroxidases (GPx1), methionine sulfoxide re-
ductase (MsrB1), and three thyroid hormone deiodinases (DIs).
As shown in Table 1, the functions of several selenoproteins have
been established, but the majority of selenoproteins have no known
functions. Indeed, besides TRs, GPxs, MsrB1, DIs, and SPS2, the speciﬁc
reactions catalyzed by selenoproteins are not known. However, con-
servation of selenoproteins among species and preservation of the
complex biosynthetic pathway for their production indicate the im-
portance of this class of proteins. So far, the common feature of all
selenoproteins with the identiﬁed functions is their participation in
oxidoreductase reactions. This type of reaction is important in intra-
cellular redox homeostasis and antioxidant defense. GPxs (and possi-
bly the N-terminal domain of SelP) are capable of reducing various
peroxides [13,14]. TRs and MsrB1 participate in the reduction of dis-
ulﬁdes and methionine (Met) sulfoxide residues in proteins, respec-
tively [15–18]. DIs catalyze reductive removal of iodine (I) from the
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thyroid hormones [19,20]. Sep15, SelM, SelH, SelS, SelK, SelN, SelT,
SelW are less characterized, whereas almost no studies have been
done on SelV, SelO, and SelI. Most likely, many of these proteins are
also oxidoreductases with Sec in the active site. More than half of
mammalian selenoproteins are characterized by the thioredoxin-
like fold. This fold is a two-layer α/β/α sandwich structure that in-
cludes a conserved CxxC motif (i.e., two Cys separated by two other
residues). In some cases, one of the Cys residues can be substituted
with Ser or Thr. This fold is especially common for enzymes that cat-
alyze formation or isomerization of disulﬁde bonds or perform other
functions that change the redox state of cysteine residues. In addition,
at least 6 out of 25 selenoproteins (Sep15, SelK, SelM, SelN, SelS, and
SelT) reside in the ER lumen, an additional selenoprotein (D2 or Dio2)
is associated with ER membranes (its catalytic site faces the cytosol),
and several secreted selenoproteins pass through this compartment.
The enrichment of the ER with selenoproteins suggests the roles ofTable 1
Mammalian selenoproteins: localization and functions.
Selenoprotein Localization Function
15 kDa selenoprotein (Sep15) ER –Trx-like fold
–regulated by ER st
–interacts with UD
–potentially involve
Thyroid hormone deiodinase 1 (DI1, Dio1) Plasma membrane –removes iodine fro
–catalyzes deiodina
Thyroid hormone deiodinase 2 (DI2, Dio2) ER –converts T4 to T3
Thyroid hormone deiodinase 3 (DI3, Dio3) Plasma membrane –catalyzes deiodina
Glutathione peroxidase 1 (GPx1) Cytosol –GSH-dependent d
Glutathione peroxidase 2 (GPx2) Cytosol –GSH-dependent d
in the intestine and
Glutathione peroxidase 3 (GPx3) Plasma –GSH-dependent d
and secreted to pla
Glutathione peroxidase 4 (GPx4, PHGPx) Cytosol
Mitochondria
nucleus (testis-speciﬁc)
–has cytosolic, nucl
–protects lipids fro
Glutathione peroxidase 6 (GPx6) Cytosol –GSH-dependent d
(enriched in the olf
Selenoprotein H (SelH) Nucleus –Trx-like fold
–protects cells from
–AT-hook family pr
genes responsible f
Selenoprotein I (SelI) Membrane unknown function
Selenoprotein K (SelK) ER membrane –modulates Ca2+ in
–component of ERA
Selenoprotein M (SelM) ER –Trx-like fold
–protects neurons f
Selenoprotein N (SelN, SEPN1, SelN1) ER membrane –expressed in skele
–controls redox sta
channel (ryanodine
affects Ca2+ homeo
–mutations in SelN
Selenoprotein O (SelO) Mitochondria –unknown function
Selenoprotein P (SelP) Plasma –Se transport to pe
Selenoprotein R (SelR, MsrB1, Selx1) Cytosol –reduces methionin
Selenoprotein S (SelS, SEPS1, Tanis, VIMP,
and SELENOS)
ER membrane –upregulated upon
– ERAD component
SPS2 Cytosol –synthesis of seleno
Selenoprotein T (SelT) ER and Golgi –Trx-like fold
–redox regulation
–plays a role in cell
Thioredoxin reductase 1 (TR1, Txnrd1) Cytosol –reduces the oxidiz
–has at least 6 isofo
Thioredoxin/glutathione reductase
(TGR, TR2, Txnrd3)
Cytosol –has a glutaredoxin
–catalyzes a variety
–expressed in sperm
Thioredoxin reductase 3 (Txnrd2, TR3) Mitochondria –reduces the oxidiz
Selenoprotein V (SelV) Cytosol –Trx-like fold
–unknown function
–expressed in sperm
Selenoprotein W (SelW) Cytosol –Trx-like fold
–unknown function
–expressed in skeleselenoproteins in ER-associated pathways, such as protein secretion/
modiﬁcation (Sep15, SelM [21]) and ER-associated protein degrada-
tion ERAD (SelS, SelK [22–24]).2. Mouse models for studying selenoproteins
Knockout (KO) and transgenic models can be used for evaluating
protein functions as well as for their impact on physiology and pa-
thology. To examine selenoprotein functions, a number of mouse
models have been developed and characterized. Generally, these
models can be divided into two groups. The ﬁrst group includes ani-
mals lacking (or overexpressing) one or two selenoproteins. The sec-
ond group includes various mouse models characterized by the
altered selenoprotein biosynthesis pathway. These animals develop
systemic selenoprotein deﬁciency. The use of these animal groups is
discussed in the following sections.References
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Severalmousemodels with targeted inactivation of one or two sele-
noproteins have been developed and characterized thus far [25,26].
Their overview is given in Table 2. Three selenoproteins were found to
be essential for embryogenesis: TR1, TR3 and GPx4. Knockout of cyto-
solic TR1 leads to embryonic death between days E8.5 and E10.5
[27,28]. While the cardiomyocyte-speciﬁc TR1 KOmice developed nor-
mally, the neuronal system (NS)-speciﬁc TR1 KO caused severe neuro-
logical symptoms, such as ataxia and tremor [29]. These symptoms
were the result of cerebellar hypoplasia, abnormal foliation, perturbed
lamination and reduced proliferation of granule cell precursors in the
cerebellum [29]. Mitochondrial TR3 KO induced embryonic lethality be-
tween days E13.5 and E15.5. Compared to controls, embryos were
smaller, developed anemia and showed high levels of liver apoptosis.
NS-speciﬁc TR3 KOmice developed normally without signs of neurode-
generation; however, the cardiomyocyte-speciﬁc TR3 KO mice died
from the heart failurewithin a few hours of birth [30]. Disruption ofmi-
tochondrial TR3 in B and T cells did not affect viability and functions of
immune cells [31]. Similar to mice, TR3 polymorphismwas found to be
associated with dilated cardiomyopathy in humans. Both nucleotide
substitutions were in the open reading frame and were part of the
FAD-binding domain [32].
GPx4 is another essential selenoenzyme: its homozygous genetic
inactivation was found to be lethal by E7.5 [33–35]. GPx4 is repre-
sented by cytosolic (cGPx4), nuclear (nGPx4) and mitochondrial
(mGPx4) isoforms. These isoforms are synthesized from the same
gene by alternative initiation of transcription and differ by their N-
terminal sequences. nGPx4 expression is driven by its own testes-
speciﬁc promoter, which lies inside the ﬁrst intron of the cytosolic
GPx4 transcript [36]. The role of GPx4 in sperm maturation was sup-
ported by the ﬁnding that this protein was a structural component of
the mitochondrial capsule of male germ cells [37]. In addition,
spermatid-speciﬁc knockout of GPx4 led to infertility in mice [38].
Moreover, inducible inactivation of GPx4 in mice and primary cells
led to an increased 12/15-lipoxygenase-derived lipid peroxidation
followed by apoptosis triggered by activation of apoptosis-inducing
factor. To further access the function of each isoform, several KO/
transgenic mouse models were prepared. nGPx4 KO mice developed
normally; neither testicular structure nor fertility were affected in
mice; however, delayed sperm chromatin condensation was observed
[39]. The sequence between the two alternative translation initiation
codons corresponding to mitochondrial and cytosolic forms encodes a
mitochondrial signal peptide. Thus, introduction of the in-frame stop
codon between these start codons resulted in the speciﬁc disruption
of the mGPx4 form without affecting the expression of cGPx4.
mGPx4 KO male mice were infertile [40]. These experiments revealed
an essential role of mGPx4 in male reproduction.
KO of other GPxs did not affect viability and fertility. The major
ﬁndings with GPx KO mice are summarized in Table 2. GPx1 KO
mice did not show signiﬁcant phenotypes; however, they were
more susceptible to oxidative stress and viral myocarditis, as well as
to reoxygenation damage due to ischemia-reperfusion injury [41].
GPx2 is mainly expressed in the epithelial tissues, and its disruption
affects intestinal cells [42]. GPx1 and GPx2 double KO mice are char-
acterized by severe colitis when maintained on an atherogenic diet
[43]. Recently, GPx3 KO mice were developed [44]. Even though no
signiﬁcant phenotype was observed, this model revealed the speciﬁc
binding of GPx3 to the basement membranes of renal cortical proxi-
mal and distal convoluted tubules.
Experiments designed to understand the function of selenopro-
teins in the thyroid gave ambiguous results. Both general and liver-
speciﬁc knockout of DI1did not lead to signiﬁcant changes in the thy-
roid hormone axis. [45,46]. DI2 is expressed in the pituitary and is
thought to be a T4 sensor, which is known to be a part of the negative
feedback loop for thyroid hormone production. DI2 KO mice showedpituitary resistance to T4 [47]. In addition, DI2 was found to be impor-
tant in the conversion of T4 to T3 in peripheral tissues (T3 stimulation
is critical for the development of the auditory functions) [48,49]. DI2
activity was increased in the wild type (WT) mouse cochlea at post-
natal day 7, and then declined by day 10. This DI2 activity correlated
with the onset of hearing. This observation suggests that DI2 plays an
important role in producing local T3 for the proper cochlear develop-
ment [50]. At the same time, DI2 deﬁciency resulted in delayed co-
chlear differentiation that was the reason for irreversible deafness
of DI2 KO mice [49]. DI1/DI2 double KO mice did not augment the
phenotype of D1 or D2 KO mice; it was rather the sum of each single
KO [51]. DI3 is responsible for inactivation of T3 and T4. DI3 KO mice
showed signs of central hypothyroidism, suggesting the importance
of T3 degradation for maintaining the thyroid hormone axis [52]. D3
KO mice, like DI2 KO mice, were characterized by impaired auditory
function, but with different pathogenesis. Unlike DI2 KO, DI3 KO
mice displayed accelerated cochlear differentiation, which also
resulted in deafness. This might suggest a critical role of DI3 in local
protection of the developing tissues from premature T3 exposure
and differentiation [53].
Experiments with SelP KO mice revealed that the major function
of SelP is the transport of Se from liver to peripheral tissues [54,55].
SelP KO mice developed symptoms of general Se deﬁciency, such as
ataxia, seizures and male infertility [56,57]. All these symptoms (ex-
cept male infertility) could be rescued by an increase in dietary Se.
Apparently, SelP KO mice are a particularly well suited model to
study Se deﬁciency. Analysis of the liver-speciﬁc Sec tRNA[Ser]Sec KO
(liver Trsp KO) mice (these mice lack expression of all selenoproteins
in hepatocytes and will be discussed later in this review) showed de-
creased expression and activity of selenoproteins in peripheral tis-
sues, which conﬁrmed the transport function for hepatic SelP [58].
The levels of Se in the brain remained unaffected in liver-speciﬁc
Trsp KOmice; also, these mice did not show neurological phenotypes.
These ﬁndings suggested another essential SelP function in the brain.
Restoration of liver SelP expression in SelP KO mice restored Se trans-
port and removed symptoms associated with Se deﬁciency [59]. Thus,
hepatocyte-derived SelP provides the major Se supply for kidney, tes-
tis and brain. However, under Se deﬁciency, overexpression of SelP in
the liver was unable to rescue the phenotypes of SelP KO mice, which
indicates the importance of local SelP production to support seleno-
protein biosynthesis under limiting Se conditions [59]. SelP was
found to be recognized by two receptors: ApoER2 (mostly in the tes-
tes) and megalin. Mice, lacking these receptors demonstrated Se deﬁ-
ciency in testes and kidney proximal tubule epithelial cells,
respectively [60,61]. SelP consists of two parts. The N-terminal region
contains a conserved UxxC motif, which is part of the domain charac-
terized by the thioredoxin-like fold [62]. The C-terminal part of SelP
contains multiple Sec residues and is involved in providing Se for
the synthesis of other selenoproteins. Deletion of the C-terminal re-
gion of SelP resulted in a milder phenotype compared to the KO of
the entire protein. Overall, the C-terminus plays a critical role in Se
transport [63]. Infection of mice lacking the C-terminal domain of
SelP with the African tripanosomiasis resulted in lower tissue injury
in comparison with SelP KO mice. These mice also showed decreased
production of reactive oxygen species and decreased apoptosis in
liver immune cells, increased parasite clearance capacity of myeloid
cells, and increased survival. All these observations indicate that the
N-terminal part of SelP plays an important role in these processes
[64].
Recently, three additional KO models were described [65]. A KO of
MsrB1 did not lead to strong phenotypes: the KO mice were viable
and fertile. However, various tissues of MsrB1 KO mice were charac-
terized by a decreased level of MsrA (methionine sulfoxide reductase
speciﬁc for the S-diastereomer of Met sulfoxide) and increased levels
of malondialdehyde, protein carbonyls, protein Met sulfoxide, as well
as higher levels of oxidized glutathione and reduced levels of free and
Table 2
Knockout of individual selenoprotein genes in mice.
Gene Approach Phenotype References
GPx1 Whole body –No gross phenotypes
–Susceptibility to oxidative stress and viral myocarditis
–Acceleration of cardiac hypertrophy and dysfunction
–Reduced blood insulin and reduced islet β-cell mass in the pancreas
[13,139]
GPx2 Whole body –No gross phenotypes
–Increased apoptosis in colon crypt cells during Se deﬁciency
[42]
GPx1+GPx2 Whole body –Microﬂora-dependent intestinal colitis
–Decreased levels of Paneth cells
[43]
GPx3 Whole body –No gross phenotypes [44]
GPx4 Whole body –Embryos die at E7.5 [33]
GPx4 Neuron speciﬁc –Severe neuodegeneration [34,36]
GPx4 Spermatid-speciﬁc –Male infertility [38]
nGPx4 Whole body –Delayed sperm chromatin condensation
mGPx4 Whole body –Male infertility
TR1 Whole body –Embryos die at between E8.5 and E10.5 [27]
TR1 Cardiomyocyte-speciﬁc –No gross phenotype [27]
TR1 Neuron-speciﬁc –Neurological symptoms, including tremor and ataxia as a
result of cerebral hypoplasia
[29]
TR3 Whole body –Embryos die at between E13.5 and E15.5 [30]
TR3 Cardiomyocyte-speciﬁc –Heart failure [30]
TR3 Neuron-speciﬁc, T-and B cells speciﬁc –No gross phenotype [30,31]
DI1 Whole body –No gross phenotypes
–Increased iodine excretion
[46]
DI2 Whole body –Pituitary resistance to T4
–Impaired thermogenic response to cold
–At thermoneutral conditions, high fat diet induced glucose
intolerance, and exacerbated hepatic steatosis
–Poor hearing, poorly differentiated sensory epithelium
[48,49]
DI3 Whole body –Reduced levels of circulating T4 and T3
–Retarded development
–Deafness with premature cochlear differentiation
[52,53]
DI1+DI2 Whole body –Mild hypothyroidism
–The sum of DI1 KO and DI2 KO phenotypes
[51]
SelP Whole body –Neuronal degeneration, leading to ataxia and seizures
–Reduced selenoprotein expression in peripheral tissues
–Male infertility
[54–56]
MsrB1 Whole body –No gross phenotypes
–Increased markers of oxidative stress
[65]
Sep15 Whole body –Congenital cataract [67]
SelK Whole body –No gross phenotypes
–Impaired function of immune cells
[66]
SEPN1 Whole body –Limited motility and body rigidity in response to physical exercise
–Poor muscle regeneration due to age and injury induced SC loss
[69,70]
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KO mice.
Systemic inactivation of SelK in mice also did not affect viability
and reproduction [66]. However, as a result of the receptor mediated
Ca2+ ﬂux, SelK KO mice showed compromised functions of immune
cells, including T cell proliferation, T cell and neutrophil migration,
and Fcγ receptor-mediated oxidative burst in macrophages; they
also showed higher susceptibility to viral infection.
Unexpected results were obtained from the analysis of the mouse
model characterized by targeted inactivation of the Sep15 gene. These
Sep15 KO mice developed congenital nuclear cataracts. Sep15 mRNA
was enriched during lens development, which suggested Sep15 func-
tion in lens formation. These cataracts did not appear to be due to se-
vere oxidative stress or glucose dysregulation and presumably are
associated with improper folding status of lens proteins caused by
Sep15 deﬁciency [67].
Genetic defects in SEPN1 gene are associated with a human disorder
called SEPN1 related myopathy, which includes early-onset muscle atro-
phy, myotendinous contractures andmuscle weakness [68]. These symp-
toms lead to respiratory insufﬁciency, spine rigidity and severe scoliosis.
Recently, a mouse model for SelN (Sepn1) deﬁciency was developed
and characterized. Although SEPN1 KOmice showed normal embryogen-
esis and growth, they demonstrated limited motility and body rigidity
during physical exercise [69]. By 4 months of age, these animals displayeda reduced pool of muscle satellite cells (SC), which are essential for adult
muscle growth and repair. SelN expressionwas drastically increased dur-
ing muscle regeneration followed by cardiotoxin-induced injury. Under
these conditions, SelN KO mice showed poorer recovery, characterized
by lower injured-to-colateral muscle mass ratio and excessive SC loss.
The essential role of SelN in SC homeostasis is consistent with the obser-
vation that biopsies from patients with SEPN1 related myopathies
showed a signiﬁcant SC loss [70].
There are several selenoproteins, which are still poorly character-
ized, and which would beneﬁt from the development and character-
ization of KO models. These proteins include SPS2, SelI, SelO, SelS,
SelT, SelV, and SelW.
2.2. Overexpression of selenoproteins in mice
Besides selenoprotein gene KO mice, several studies described an-
imals with overexpression of individual selenoproteins. One of the
best such models is the GPx-overexpressing mice (GPx1oe). These
animals were shown to develop hyperglycemia and hyperinsuline-
mia, and they also developed high levels of blood insulin and in-
creased islet β-cell mass [71–73]. It should be noted that similar
phenotypes were observed in Type 2 diabetes models. When main-
tained on a high fat diet, these mice developed obesity and insulin re-
sistance, unlike GPx1 KO mice, which showed reduced insulin levels
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might be explained by insufﬁcient ROS-mediated signaling in islet
β-cells. In a different model of diabetes, expression of GPx1 had a
beneﬁcial effect. Here, overexpression of GPx1 in the islet β-cell of
the db/db mice alleviated hyperglycemia at an early age and
completely reversed it by 20 weeks of age [74]. Since redox signaling
plays a critical role in β-cell signal transduction, both deﬁciency and
excess of GPx1 are capable of deregulating signaling pathways.
These results suggest the importance of controlled GPx1 expression
for prevention of Type 2 diabetes.
Another research group developed mice with transgenic overex-
pression of mitochondrial GPx4 (mGPx4) [75]. Compared to littermate
controls, these mice developed attenuated cardiac dysfunction in re-
sponse to ischemia/reperfusion injury. Overexpression of mGPx4 re-
duced the levels of lipid peroxidation and slightly increased the
activity of the electron transport chain (ETC) complexes I, III, and IV.
Another example of overexpression of a selenoprotein in an ani-
mal model is the overexpression of SelM in rats [76]. These animals
showed a better response to oxidant treatment. When fed with high
Se diet, transgenic rats showed altered ERK signal transduction in
the brain, which was characterized by inhibition of the alpha/
gamma-secretase activity and Tau protein phosphorylation. These ob-
servations suggest a possible protective role of SelM in the Alzhei-
mer's disease [77].
3. Mouse models targeting the Sec biosynthesis pathway
Inactivating a single selenoprotein in mice can provide informa-
tion about its function and reveal phenotypes associated with its de-
ﬁciency. However, targeting the Sec incorporation machinery allows
modulation of the expression of subsets or even all selenoproteins.
Many such models have been developed.
3.1. Sec incorporating machinery
In eukaryotic cells, Sec biosynthesis and incorporation is a com-
plex multi-stage process [7,8,78,79]. The overall pathway of Sec in-
corporation is illustrated in Fig. 1. Sec is synthesized on its own
tRNA, tRNA[Ser]Sec, which is the product of the Trsp gene. Initially,
this tRNA is charged with Ser, forming Ser-tRNA[Ser]Sec. This reaction
is catalyzed by seryl-tRNA synthetase (SerRS). Ser-tRNA[Ser]Sec is fur-
ther phosphorylated by phosphoseryl-tRNA[Ser]Sec kinase (PSTK).
The Se donor compound for the Sec biosynthesis, selenophosphate,
is synthesized by selenophosphate synthetase 2 (SPS2). Sec synthase
(SecS or SepSecS) catalyzes the pyridoxal phosphate-dependent reac-
tion which results in Sec-tRNA[Ser]Sec formation. Once formed, Sec-
tRNA[Ser]Sec associates with EFSec and SBP2, and this supramolecular
complex is translocated to the nucleus [80]. SBP2 recognizes the
SECIS element, which is located in the 3′-UTR of selenoprotein
mRNAs. This complex then supports the incorporation of Sec in re-
sponse to the in-frame-UGA codon. There are several features which
are critical for proper function of the pathway: 1) as shown in
Fig. 1, SBP2 and EFSec shuttle between the nucleus and cytosol. This
allows binding selenoprotein mRNAs in the nucleus and inhibition
of the nonsense mediated decay induced by the in-frame stop
codon [81]; 2) SPS2 is itself a selenoprotein, forming a positive feed-
back loop [82]; 3) recently, it was found that SPS2 can also synthesize
thiophosphate, promoting incorporation of Cys in place of Sec; in
mice maintained on the Se-deﬁcient diet, insertion of Cys at UGA
codon of TR1 equaled that of Sec [83]; and 4) Sec tRNA[Ser]Sec is a
unique tRNA, which undergoes multiple modiﬁcations, further regu-
lating Sec incorporation. These modiﬁcations include isopentenylade-
nosine modiﬁcation at position 37 and methylcarboxymethyl-5′-
uridine (mcm5U) at position 34. The last step in Sec-tRNA[Ser]Sec mat-
uration is the methylation of mcm5U, which may be assisted by
Secp43 and results in the formation of methylcarboxymethyl-5′-uridine-2′-O-hydroxymethylribose (mcm5Um) [84]. This process is
highly sensitive to the primary, secondary and tertiary structure of
the tRNA as well as to overall Se status. mcm5U supports the
synthesis of “housekeeping” selenoproteins, such as GPx4, TR1 and
TR3, whereas the methylated tRNA is needed for expression of
“stress-related” selenoproteins, such as GPx1, GPx3, and MsrB1. This
change in selenoprotein expression pattern is commonly observed
during Se deﬁciency, but the precise molecular mechanism is
unknown.
There are several ways to regulate efﬁciency of Sec incorporation.
In order to modulate expression of selenoproteins, the easiest way is
to change the levels of dietary Se. To examine the effects of dietary Se
on various health parameters, one can adjust Se concentration in ro-
dent chow. For example, 0.1 ppm Se in the diet corresponds approx-
imately to the human Recommended Dietary Allowance for adults,
whereas 0.4 ppm Se may correspond to the diet supplemented with
200 μg Se/day, which is the dose most often used in clinical trials in-
volving Se [85–87]. This approach was successfully applied to exam-
ine Se function in diabetes [88], cancer [89], the immune response
[90,91], etc. The disadvantage of this approach, however, is that
with the change in dietary Se in order to regulate selenoprotein ex-
pression, the levels of low molecular weight Se compounds are also
changed, which might itself inﬂuence certain pathways.
3.2. Trsp transgenic mouse models
Stable expression of mutant Trsp was shown to severely affect sele-
noprotein biosynthesis by interfering with the Sec incorporation path-
way by a dominant-negative mechanism. According to this hypothesis,
twomousemodelswere generated. In theﬁrstmodel, A37was substitut-
ed with G37 [92], and in the second, T34 was replaced with A34 [93].
Both models lacked mcm5Um34; thus, expression of stress-related sele-
noproteins was severely reduced, whereas expression of housekeeping
selenoprotein genes was little affected. The effect of G37 transgene was
tissue-speciﬁc: it was signiﬁcant in the liver and kidney, but not in testes
[92]. The G37 transgenic mice were studied for various health parame-
ters. These mice were found to be more susceptible to viral infection
[94], colon cancer [95] and X-ray damage [96]. Crossing the G37 and
C3/Tag mice provided a good model for studying the function of seleno-
proteins in prostate cancer. Such mice were found to accelerate the de-
velopment of prostatic epithelial neoplasia (PIN), suggesting a
protecting role of selenoproteins during prostate cancer development
[97]. The G37mice demonstrated enhancedmuscle growth in the setting
thatmodeled exercise overload. These data correlatedwith the initial ac-
tivation of the insulin signaling pathway, which included increased Akt
and p70 phosphorylation [98]. Abnormal insulin signaling might be, in
part, the reason for glucose intolerance and lead to a diabetes-like pheno-
type, that was recently observed in the G37 mice [88].
3.3. Trsp knockout mouse models
Another approach of inactivating selenoprotein function in mice is
to target the Trsp gene. The complete KO of Trsp leads to embryonic
lethality [99], but a conditional removal of Trsp is possible [100]. De-
velopment of the tissue-speciﬁc KO models helped examining impor-
tant functions of selenoproteins in the heart and skeletal muscle,
endothelial cells [101], skin [102], bone [103], neurons [104] and
the immune cells (macrophages, T cells and hematopoietic tissues)
[105–107], and also studying more dispensable selenoprotein func-
tions in the liver [58,108], mammary gland [100] and podocytes
[109]. KO of Trsp in the endothelial cells led to embryonic death at
day E14.5 due to necrosis of the central nervous system, erythrocyte
immaturity and subcutaneous hemorrhage. Mice with the myocyte-
speciﬁc Trsp KO died 12 days after birth from acute myocardial failure
[101]. Deletion of Trsp in the skin resulted in runt phenotype, epider-
mal neoplasia, and abnormal development of the hair follicles.
Fig. 1.Mechanisms of eukaryotic Sec biosynthesis and incorporation. Sec tRNA[Ser]Sec is initially charged with Ser, which is further phosphorylated by PSTK. SPS2 facilitates the syn-
thesis of selenophosphate, the selenium donor compound. SecS then catalyzes Sec formation. SECp43 may be involved in the methylation of Sec tRNA[Ser]Sec at the A34 position.
Protein factors, including SBP2 and EFSec, bind the SECIS element, located in the 3′-UTRs of selenoprotein mRNAs. After translocation to the cytosol, protein factors support inter-
action with the ribosome and Sec incorporation.
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Thus, selenoproteins have a role in maintaining skin integrity [110].
Osteo-chondroprogenitor-speciﬁc Trsp KO mice showed multiple
skeletal abnormalities, including growth retardation, abnormal
epiphyseal plates, delayed ossiﬁcation, and chondronecrosis of carti-
lage [103]. The neuron-speciﬁc Trsp KO induced severe neurodegen-
eration in the hippocampus and led to the absence of certain
interneurons [110] (similar to what was observed in the neuron-
speciﬁc GPx4 KO model). Besides, these mice showed degeneration
of the Purkinje and granule cells that led to cerebral hyperplasia. In
several studies, Se modulated the immune response. To understand
the function of selenoproteins in immune cells, T and B cell-speciﬁc
Trsp KO mice were developed. The T-cell-speciﬁc Trsp KO decreased
the pool of mature T-cells and impaired T-cell dependent antibody re-
sponse. Lack of antioxidant enzymes caused extensive oxidative
stress and weak proliferation in response to T-cell receptor stimula-
tion [106]. Macrophage speciﬁc Trsp KO mice showed impaired inva-
siveness, which might be explained by hyperproduction of ROS and
altered expression of extracellular matrix proteins [105]. Ablation of
the Trsp gene in hematopoietic tissues resulted in anemia, which
led to an increased production of erythroid progenitors in the bone
marrow as well as to thymus atrophy [107]. The liver-speciﬁc Trsp
KO induced expression of phase II enzymes, including various GSTs
[111]. By preventing SelP synthesis and secretion, the liver-speciﬁc
Trsp KO dramatically decreased plasma SelP. Thus, these mice
showed of Se deﬁciency, which could be rescued by increased Se in-
take [93]. The mammary gland-speciﬁc Trsp KO mice showed in-
creased levels of p53 and decreased expression of BRCA1 tumor
suppressor [100]. In addition, mice carrying a knockout of Trsp in
the liver were found to have an increased apolipoprotein E (ApoE)level and elevated cholesterol levels in plasma that was accompanied
by enhanced expressed of the genes involved in cholesterol biosyn-
thesis, metabolism and transport [112]. Interestingly, transgenic
mouse models that express housekeeping, but not stress-related sele-
noproteins restored the expression of these genes (made them close
to the corresponding levels observed in WT controls). These studies
showed that housekeeping selenoproteins have a role in regulating li-
poprotein biosynthesis and metabolism and were consistent with the
earlier studies showing that selenium deﬁciency increased ApoE ex-
pression. Overall, mouse models with conditional Trsp KO turned
out to be a powerful tool for understanding functions of selenopro-
teins in various tissues.
3.4. Knockout/transgenic mouse models
An additional strategy to investigate the effect of transgene over-
expression is to develop KO/transgenic animal models. In the case of
selenoproteins, liver Trsp KO mice were crossed with the G37 or
A34 mice. In both cases, similar expression patterns of housekeeping
selenoproteins were observed. As discussed above, restoration of
housekeeping selenoprotein genes partially decreased elevated levels
of ApoE and serum cholesterol that had been observed in the liver-
speciﬁc Trsp KO. Another useful knockout/transgene mouse model
was also described [113]. STAF (Sec tRNA gene transcription activat-
ing factor) is a transcription factor for several RNA PolII and RNA
PolIII-dependent genes. In this study, the authors overexpressed
Trsp lacking the STAF binding promoter region and afterwards re-
moved the WT Trsp. Interestingly, removal of the STAF binding site
did not affect Trsp levels in the heart and testis, but showed severe re-
duction of the transgene in the liver, kidney, lung, spleen, and brain.
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and expression of stress-related selenoproteins was reduced. These
mice demonstrated the neurological phenotype similar to that of
SelP KO mice. These ﬁndings indicated the importance of the STAF
binding region in regulation of Sec tRNA[Ser]Sec expression and its
proper modiﬁcation status.
4. Concluding remarks
Development of appropriate animal models is a critical step in the
characterization of biological functions of genes. A great deal of re-
search in the area of Se biology was devoted to the understanding
of functions of this micronutrient and selenoproteins in health and
disease. It is clear from the discussion above that the functions of sev-
eral selenoproteins and their forms could not have been determined
without the use of appropriate KO models. However, there are also
several obstacles resulting from the analysis of human diseases asso-
ciated with the genetic defects in selenoprotein biosynthesis. For ex-
ample, the presence of hypomorphic alleles of SBP2 gene was
associated with retarded growth due to thyroid axis imbalance in
children. At the same time, these patients experienced myopathy,
waddling gait and mental retardation [114,115] and were character-
ized by bilateral hearing loss and infertility. Recent research demon-
strated that mutations in SecS gene are associated with the
development of autosomal-recessive progressive cerebellocerebral
atrophy [116] and that the observed phenotypes could be partially
reproduced in the corresponding KO animal models. Indeed, analysis
of the SelP KO mice could explain all symptoms, except for abnormal-
ities in the thyroid function. While hypothyroidism is one of the ﬁrst
complaints in patients with impaired Sec incorporation pathway, in
mice this effect is less pronounced. There are also several open ques-
tions. For example, mice maintained on the Se-deﬁcient diet survive
for more than one year with no visible abnormalities. The lifespan
of the G37 transgenic mice was not affected: these mice were fully
fertile, and did not develop symptoms similar to those in the patients
with defects in SBP2. Understanding the reasons for the differences
between human and mouse phenotypes could provide important
new insights into the role of Se, Sec and selenoproteins in human
health, and also into the molecular mechanisms of Sec incorporation
and selenoprotein function. This research may also reveal novel regu-
latory mechanisms.
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